Teva Pharmaceutical Industries Ltd Reaches New 12-Month High at $45.98 (TEVA)
Shares of Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) hit a new 52-week high during trading hours on Wednesday, Analyst Ratings.Net reports. The company traded as high as $45.98 and last traded at $44.98, with a volume of 9,814,544 shares trading hands. The stock had previously closed at $44.10.
Several analysts have recently commented on the stock. Analysts at TheStreet upgraded shares of Teva Pharmaceutical Industries Ltd from a “hold” rating to a “buy” rating in a research note to investors on Wednesday. Separately, analysts at CRT Capital raised their price target on shares of Teva Pharmaceutical Industries Ltd from $50.00 to $55.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Finally, analysts at Citigroup Inc. raised their price target on shares of Teva Pharmaceutical Industries Ltd from $47.00 to $50.00 in a research note to investors on Tuesday. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $45.15.
Teva Pharmaceutical Industries Ltd has a one year low of $36.26 and a one year high of $45.46. The stock’s 50-day moving average is $41.37 and its 200-day moving average is $39.66. The company has a market cap of $37.831 billion and a P/E ratio of 31.30.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) is a global pharmaceutical and drug company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.